Achaogen Company Profile (NASDAQ:AKAO)

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

Achaogen, Inc. (NASDAQ:AKAO) released its earnings results on Monday, May, 8th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.39. The company earned $7.46 million during the quarter, compared to analyst estimates of $3.81 million. Achaogen had a negative net margin of 212.71% and a negative return on equity of 119.78%. The company's quarterly revenue was up 27.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.66) EPS. View Achaogen's Earnings History.

Achaogen is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Achaogen.

9 equities research analysts have issued 1 year price targets for Achaogen's stock. Their forecasts range from $10.00 to $31.00. On average, they expect Achaogen's stock price to reach $25.88 in the next year. View Analyst Ratings for Achaogen.

Here are some recent quotes from research analysts about Achaogen stock:

• 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (7/17/2017)
• 2. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
• 3. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
• 4. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Achaogen saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 6,163,446 shares, an increase of 55.2% from the June 15th total of 3,970,560 shares. Based on an average trading volume of 1,233,021 shares, the days-to-cover ratio is presently 5.0 days. Approximately 24.2% of the company's shares are short sold.

Some companies that are related to Achaogen include Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), PTC Therapeutics (PTCT), NeuroDerm (NDRM) and ZIOPHARM Oncology (ZIOP).

Achaogen's management team includes the folowing people:

• Bryan E. Roberts Ph.D., Chairman of the Board
• Kenneth J. Hillan, President, Chief Executive Officer, Director
• Blake Wise, President, Chief Operating Officer
• Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
• Lee Swem, Senior Vice President, Chief Scientific Officer
• Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy
• Janet Dorling, Chief Commercial Officer
• Alan B. Colowick M.D., Director
• John C. Doyle, Director
• Halley E. Gilbert Esq., Director

Achaogen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hartwell J M Limited Partnership (0.08%) and Bank of Montreal Can (0.03%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Achaogen's stock was acquired by a variety of institutional investors in the last quarter, including Hartwell J M Limited Partnership and Bank of Montreal Can. View Insider Buying and Selling for Achaogen.

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Achaogen stock can currently be purchased for approximately $21.90.